On this week’s episode, hosts Daphne Zohar, Bruce Booth, Dawn Bell and Tim Opler are joined by Rajiv Kaul, portfolio manager in the equity division at Fidelity Investments, to discuss the latest data, financial and M&A news in the industry. The group begins by discussing an optimistic outlook for the biotech industry as financial trends seem to be shifting, noting that some of the most important breakthroughs in science and tech have followed challenging economic periods. They dive into the topic of opportunity assessment from different points of view in the industry – from pharma to biotech to public and private investment – sharing perspectives on weighing risk, novelty and values of new therapeutics. The hosts also share insight into the recent theme of consolidation with a few unique mergers and acquisitions from this week between Angion and privately held Elicio Therapeutics, Leap Therapeutics’ merger with Flame Biosciences and Sun Pharma’s acquisition of Concert Pharmaceuticals. Other news covered includes Moderna’s promising RSV vaccine data and the FDA’s denial of Lilly’s Alzheimer’s accelerated approval. Ending on a positive note, the group reflects on their excitement about the innovation in the biotech space.

Community of experts and insiders joining Biotech Hangout (formerly known as Biotech Clubhouse) include Daphne Zohar, Josh Schimmer, Bruce Booth, Tim Opler, Chris Garabedian, Michal Preminger, Dawn Bell, Rob Perez, Otello Stampacchia and more.